This is a working overview of reconstitution, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-03. Anything still debated is marked as such rather than presented as settled.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
=== Hopman Cup === Zverev represented Germany at the Hopman Cup for four consecutive years from 2016 through 2019 with three different partners. In 2016, he competed with Sabine Lisicki. The duo won their tie against the French team, with Zverev winning both his singles and mixed doubles matches. However, they were shut out against Great Britain and Australia Green and did not advance to the final. The following year, he entered the competition with Andrea Petkovic. While the pair only won their tie against Great Britain, Zverev also defeated Federer in singles in his first tournament back from injury. Zverev enjoyed more success in 2018 and 2019, pairing with Angelique Kerber. In their first year together, they advanced to the final, primarily on the strength of the pair winning all three of their mixed doubles matches. In the final against Switzerland, Zverev lost his singles match to Federer. Although Kerber won her singles match against Belinda Bencic, they lost the decisive mixed doubles rubber. They returned in 2019 and again reached the final to set up a rematch of the previous year's final with Federer and Bencic. In a round-robin group with Australia, France, and Spain, the two of them won all six of their singles matches, but lost two of their three mixed doubles matches against Australia and France. Like the previous year, the final was decided by the mixed doubles match after Federer defeated Zverev and Kerber defeated Bencic. With the Fast4 format, the match went to three sets. In the third set tiebreak, both teams had a match point at 4–4.
=== Razin and Pugachev Rebellions === As a largely independent nation, the Cossacks had to defend their liberties and democratic traditions against the ever-expanding Muscovy, succeeded by the Russian Empire. Their tendency to act independently of the Tsardom of Russia increased friction. The Tsardom's power began to grow in 1613, with the ascension of Mikhail Romanov to the throne following the Time of Troubles. The government began attempting to integrate the Cossacks into the Russian Tsardom by granting elite status and enforcing military service, thus creating divisions among the Cossacks themselves as they fought to retain their traditions. The government's efforts to alter their traditional nomadic lifestyle resulted in the Cossacks being involved in nearly all the major disturbances in Russia over 200 years, including the rebellions led by Stepan Razin and Yemelyan Pugachev.
=== Xenobiotics === Numerous drugs can raise GGT levels, including phenobarbitone and phenytoin. GGT elevation has also been occasionally reported following nonsteroidal anti-inflammatory drugs (including aspirin), St. John's wort and kava.
== Electronic circuits == A digital circuit is supposed to be found in a small number of stable digital states within a certain amount of time after an input change. However, if an input changes at the wrong moment a digital circuit which employs feedback (even a simple circuit such as a flip-flop) can enter a metastable state and take an unbounded length of time to finally settle into a fully stable digital state.
In subsequent years, the business developed and Lonza was the first fine chemical company to enter into a strategic partnership with SKF. In a similar way, Fine Organics, UK became the supplier of the thioethyl-N'-methyl-2-nitro-1,1-ethenediamine moiety of ranitidine, the second H2 receptor antagonist, marketed as Zantac by Glaxo. Other pharmaceutical and agrochemical companies gradually followed suit and started outsourcing the procurement of fine chemicals. For example, F.I.S., Italy, partnered with Roche, Switzerland for custom manufacturing precursors of the benzodiazepine class of tranquilizers, such as Librium (chlordiazepoxide HCl) and Valium (diazepam). The growing complexity and potency of new pharmaceuticals and agrochemicals requiring production in multipurpose, instead of dedicated, plants and, more recently, the advent of biopharmaceuticals, has had a major impact on the demand for fine chemicals and the evolution of the fine chemical industry as a distinct entity. For many years, the life science industry continued considering captive production of the active ingredients of their drugs and agrochemicals as a core competency. Outsourcing was used only in exceptional cases, such as capacity shortfalls, processes requiring hazardous chemistry or new products, where uncertainties existed about the chance of a successful launch.
Sources: en.wikipedia.org
=== Grey market use === Suvomipic has attracted an unusual amount of attention for an investigational drug, such as in the r/Tressless subreddit about hair loss on Reddit. A large group of r/Tressless members, having believed that JXL069 is suvomipic, are known to have sourced JXL069 from China in 2025 in an effort to treat their hair loss. This included sending a sample to an analytical testing lab to confirm the compound's authenticity. Pelage Pharmaceuticals says that it does not endorse such use and has explicitly stated that suvomipic is not JXL069. Suvomipic is also said to not be JXL082. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed that suvomipic is in fact JXL069.
=== Other === Escitalopram may reduce premenstrual symptoms in women with premenstrual syndrome and premenstrual dysphoric disorder. It seems to be more effective when taken continuously compared to luteal phase administration. It is also occasionally prescribed off-label for insomnia secondary to a mental disorder, and vasomotor symptoms (hot flashes) associated with menopause.
== Medical uses == Treatment of PCP caused by Pneumocystis jirovecii Prevention of PCP in adults with HIV who have one or both of the following: History of PCP CD4+ count ≤ 200mm³ Treatment of leishmaniasis Treatment of African trypanosomiasis caused by Trypanosoma brucei gambiense Balamuthia infections Pentamidine is classified as an orphan drug by the U.S. Food and Drug Administration
=== Other similarities === Biologists often point to the universality of many aspects of cellular life as supportive evidence to the more compelling evidence listed above. These similarities include the energy carrier adenosine triphosphate (ATP), and the fact that all amino acids found in proteins are left-handed. It is, however, possible that these similarities resulted because of the laws of physics and chemistry - rather than through universal common descent - and therefore resulted in convergent evolution. In contrast, there is evidence for homology of the central subunits of transmembrane ATPases throughout all living organisms, especially how the rotating elements are bound to the membrane. This supports the assumption of a LUCA as a cellular organism, although primordial membranes may have been semipermeable and evolved later to the membranes of modern bacteria, and on a second path to those of modern archaea also.
Sources: en.wikipedia.org
=== 1990s === 1990: Antonia Novello became the first woman, first person of color, and first Hispanic to serve as Surgeon General of the United States. 1991: Doris Malkin Curtis became the first woman president of the Geological Society of America. 1992: Edith M. Flanigen became the first woman awarded the Perkin Medal (widely considered the highest honor in American industrial chemistry) for her outstanding achievements in applied chemistry. The medal especially recognized her syntheses of aluminophosphate and silicoaluminophosphate molecular sieves as new classes of materials. 1992: Mae Jemison becomes the first Black woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour. 1993: Ellen Ochoa became the first Hispanic woman to go to space when she served aboard the Space Shuttle Discovery. 1998: Nurse Fannie Gaston-Johansson became the first African-American woman tenured full professor at Johns Hopkins University. 1998: Rita R. Colwell became the first female director of the National Science Foundation.
=== US introduction === The Turkestan cockroach was first noticed in the US in 1978, around the former Sharpe Army Depot in California, followed shortly after by appearances at Fort Bliss in Texas and several other military bases. Researchers believe the species arrived on military equipment returning from Central Asia, perhaps Afghanistan. Since then the species has been rapidly replacing the common oriental cockroach (Blatta orientalis) in urban areas of the Southwestern United States “as the most important peri-domestic species”, with advantages of laying more eggs and maturing more quickly than the oriental cockroach. “They typically inhabit in-ground containers such as water meter, irrigation, and electrical boxes, raises of concrete, cracks and crevices, and hollow block walls.” They are well established in the Southwest and parts of the Southeast, and have been reported in the Northeast. It has become established in California.
Two classes of drugs target the mevalonate pathway: statins (like rosuvastatin), which are used to reduce elevated cholesterol levels, and bisphosphonates (like zoledronate), which are used to treat a number of bone-degenerative diseases.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.